Andrew Chiou1, Bryant R England2, Harlan Sayles1, Geoffrey M Thiele2, Michael J Duryee2, Joshua F Baker3, Namrata Singh4, Grant W Cannon5, Gail S Kerr6, Andreas Reimold7, Angelo Gaffo8, Ted R Mikuls2. 1. University of Nebraska Medical Center, Omaha. 2. University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. 3. Corporal Michael J. Crescenz VAMC and University of Pennsylvania, Philadelphia. 4. Iowa City VAMC and University of Iowa, Iowa City. 5. Salt Lake City VAMC and University of Utah, Salt Lake City. 6. Washington, DC VAMC, Georgetown University, and Howard University, Washington, DC. 7. Dallas VAMC and University of Texas Southwestern. 8. Birmingham VAMC and University of Alabama at Birmingham.
Abstract
OBJECTIVE: Although hyperuricemia and gout can complicate the course of rheumatoid arthritis (RA), the impact of these factors on outcomes in RA is unclear. We undertook this study to examine associations of coexistent hyperuricemia and gout with RA disease measures, RA treatments, and survival. METHODS: Participants from a longitudinal RA study were categorized by the presence of gout and serum urate (UA) status. Groups were compared by baseline patient characteristics, RA disease activity, treatments, and comorbidities. Associations of baseline serum UA levels with all-cause and cardiovascular disease (CVD)-related mortality were examined in multivariable survival analyses. RESULTS: Of 1,999 participants with RA, 341 (17%) had serum UA concentrations of >6.8 mg/dl, and 121 (6.1%) were diagnosed with gout. There were no significant associations of serum UA concentration or gout with RA disease activity or treatment at enrollment, with the exception that those with gout were more likely to be receiving sulfasalazine and less likely to be receiving nonsteroidal antiinflammatory drugs. After adjustments for age and sex, moderate hyperuricemia (serum UA >6.8 to ≤8 mg/dl) was associated with an increased risk of CVD-related mortality (hazard ratio 1.56 [95% confidence interval 1.11-2.21]). This association was attenuated and not significant following additional adjustment for comorbidities that more commonly accompany hyperuricemia. Results corresponding with serum UA concentrations of >8.0 mg/dl were similar, although not reaching statistical significance in any model. There were no associations of baseline serum UA concentration with all-cause mortality. CONCLUSION: Our study reports the frequency of hyperuricemia and gout in patients with RA. These results demonstrate strong associations of hyperuricemia with CVD mortality in this population, a risk that appears to be driven by excess comorbidity.
OBJECTIVE: Although hyperuricemia and gout can complicate the course of rheumatoid arthritis (RA), the impact of these factors on outcomes in RA is unclear. We undertook this study to examine associations of coexistent hyperuricemia and gout with RA disease measures, RA treatments, and survival. METHODS:Participants from a longitudinal RA study were categorized by the presence of gout and serum urate (UA) status. Groups were compared by baseline patient characteristics, RA disease activity, treatments, and comorbidities. Associations of baseline serum UA levels with all-cause and cardiovascular disease (CVD)-related mortality were examined in multivariable survival analyses. RESULTS: Of 1,999 participants with RA, 341 (17%) had serum UA concentrations of >6.8 mg/dl, and 121 (6.1%) were diagnosed with gout. There were no significant associations of serum UA concentration or gout with RA disease activity or treatment at enrollment, with the exception that those with gout were more likely to be receiving sulfasalazine and less likely to be receiving nonsteroidal antiinflammatory drugs. After adjustments for age and sex, moderate hyperuricemia (serum UA >6.8 to ≤8 mg/dl) was associated with an increased risk of CVD-related mortality (hazard ratio 1.56 [95% confidence interval 1.11-2.21]). This association was attenuated and not significant following additional adjustment for comorbidities that more commonly accompany hyperuricemia. Results corresponding with serum UA concentrations of >8.0 mg/dl were similar, although not reaching statistical significance in any model. There were no associations of baseline serum UA concentration with all-cause mortality. CONCLUSION: Our study reports the frequency of hyperuricemia and gout in patients with RA. These results demonstrate strong associations of hyperuricemia with CVDmortality in this population, a risk that appears to be driven by excess comorbidity.
Authors: Bryant R England; Harlan Sayles; Ted R Mikuls; Dannette S Johnson; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: Michael Chen-Xu; Chio Yokose; Sharan K Rai; Michael H Pillinger; Hyon K Choi Journal: Arthritis Rheumatol Date: 2019-04-15 Impact factor: 10.995
Authors: Nazia Rashid; Brian W Coburn; Yi-Lin Wu; T Craig Cheetham; Jeffrey R Curtis; Kenneth G Saag; Ted R Mikuls Journal: J Rheumatol Date: 2014-12-15 Impact factor: 4.666
Authors: Om Prakash Kafle; Xi Wang; Shiqiang Cheng; Miao Ding; Ping Li; Bolun Cheng; Xiao Liang; Li Liu; Yanan Du; Mei Ma; Lu Zhang; Yan Zhao; Yan Wen; Feng Zhang Journal: Can J Psychiatry Date: 2020-11-06 Impact factor: 5.321
Authors: Sufian M Khaild; Amro M Fagir; Ziryab I Taha; Awadelkareem A Elshareef; Mohammed H Mohammed; Khalda M Saeed; Elnour M Elagib; Elwalied M Ibrahim; Jimmy William Journal: Cureus Date: 2022-04-18
Authors: Muhammad Riaz; Lina Tariq Al Kury; Noreen Atzaz; Abdullah Alattar; Reem Alshaman; Fawad Ali Shah; Shupeng Li Journal: Drug Des Devel Ther Date: 2022-04-22 Impact factor: 4.319